Potent anti-angiogenic activity of B19--a mono-carbonyl analogue of curcumin.
10.1016/S1875-5364(14)60002-9
- Author:
Li SUN
1
;
Jin LIU
2
;
Sen-Sen LIN
2
;
Wen-Ting SHI
1
;
Jing ZHU
2
;
Guang LIANG
3
;
Sheng-Tao YUAN
4
Author Information
1. Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing 210009, China.
2. Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China.
3. Wenzhou Medical College Pharmacy School, Wenzhou 325035, China.
4. Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China. Electronic address: yuanst2@yahoo.com.cn.
- Publication Type:Journal Article
- Keywords:
Angiogenesis;
B19;
Curcumin derivative;
Human umbilical vein endothelial cell (HUVEC);
R285;
Vascular endothelial growth factor (VEGF)
- MeSH:
Angiogenesis Inhibitors;
chemistry;
pharmacology;
Animals;
Aorta;
drug effects;
metabolism;
Cell Movement;
drug effects;
Curcumin;
analogs & derivatives;
pharmacology;
Extracellular Signal-Regulated MAP Kinases;
genetics;
metabolism;
Human Umbilical Vein Endothelial Cells;
cytology;
drug effects;
metabolism;
Humans;
In Vitro Techniques;
Rats;
Rats, Sprague-Dawley;
Vascular Endothelial Growth Factor A;
genetics;
metabolism;
Vascular Endothelial Growth Factor Receptor-2;
genetics;
metabolism
- From:
Chinese Journal of Natural Medicines (English Ed.)
2014;12(1):8-14
- CountryChina
- Language:English
-
Abstract:
AIM:The compound B19 (C21H22O5) is a newly synthesized, mono-carbonyl analog of curcumin that has exhibited potential antitumor effects. This present study was performed to identify the anti-angiogenic activity of this compound.
METHODS AND RESULTS:B19 inhibited migration and tube formation of human umbilical vein endothelial cells, and arrested microvessel outgrowth from rat aortic rings. In addition, B19 suppressed the neovascularization of chicken chorioallantoic membrane. Mechanistic studies revealed that B19 suppressed the downstream protein kinase activation of vascular endothelial growth factor (VEGF) by decreasing phosphorylated forms of serine/threonine kinase Akt, extracellular signal-regulated kinase, and p38 mitogen-activated protein kinase, with or without stimulating vascular endothelial growth factor (VEGF).
CONCLUSIONS:B19 exerted anti-angiogenic activity in vitro and ex vivo, which suggests that it merits further investigation as a promising anticancer angiogenesis compound.
